1. Home
  2. REGN vs MNST Comparison

REGN vs MNST Comparison

Compare REGN & MNST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REGN
  • MNST
  • Stock Information
  • Founded
  • REGN 1988
  • MNST 1985
  • Country
  • REGN United States
  • MNST United States
  • Employees
  • REGN N/A
  • MNST N/A
  • Industry
  • REGN Biotechnology: Pharmaceutical Preparations
  • MNST Beverages (Production/Distribution)
  • Sector
  • REGN Health Care
  • MNST Consumer Staples
  • Exchange
  • REGN Nasdaq
  • MNST Nasdaq
  • Market Cap
  • REGN 59.5B
  • MNST 61.0B
  • IPO Year
  • REGN 1991
  • MNST N/A
  • Fundamental
  • Price
  • REGN $654.37
  • MNST $66.56
  • Analyst Decision
  • REGN Buy
  • MNST Buy
  • Analyst Count
  • REGN 21
  • MNST 15
  • Target Price
  • REGN $779.00
  • MNST $67.79
  • AVG Volume (30 Days)
  • REGN 1.0M
  • MNST 5.1M
  • Earning Date
  • REGN 10-28-2025
  • MNST 11-06-2025
  • Dividend Yield
  • REGN 0.55%
  • MNST N/A
  • EPS Growth
  • REGN 2.88
  • MNST 0.32
  • EPS
  • REGN 41.59
  • MNST 1.60
  • Revenue
  • REGN $14,247,800,000.00
  • MNST $7,659,164,000.00
  • Revenue This Year
  • REGN $1.34
  • MNST $9.77
  • Revenue Next Year
  • REGN $5.23
  • MNST $8.41
  • P/E Ratio
  • REGN $15.49
  • MNST $42.29
  • Revenue Growth
  • REGN 2.89
  • MNST 3.70
  • 52 Week Low
  • REGN $476.49
  • MNST $45.70
  • 52 Week High
  • REGN $844.51
  • MNST $70.72
  • Technical
  • Relative Strength Index (RSI)
  • REGN 67.60
  • MNST 44.62
  • Support Level
  • REGN $625.14
  • MNST $65.92
  • Resistance Level
  • REGN $664.00
  • MNST $67.96
  • Average True Range (ATR)
  • REGN 17.50
  • MNST 1.23
  • MACD
  • REGN 4.95
  • MNST -0.42
  • Stochastic Oscillator
  • REGN 89.45
  • MNST 14.17

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

About MNST Monster Beverage Corporation

Monster Beverage is a leader in the energy drink category within the nonalcoholic ready-to-drink beverage market, generating two thirds of revenue in the US and Canada. The well-known Monster trademark includes brands such as Monster Energy, Monster Ultra, Java Monster, and Juice Monster. The firm also owns other energy drink brands, such as Reign, NOS, Burn, Bang and Mother, and brews and distributes beers and flavored malt beverages following the acquisition of a craft brewer in 2022. Monster controls branding and innovation but outsources beverage manufacturing and packaging to copackers and finished goods distribution to bottlers in the global Coca-Cola system (pursuant to a 20-year agreement inked in 2015). Coke is the largest shareholder of Monster with a 19.5% stake.

Share on Social Networks: